Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Estimating the carbon footprint of oral semaglutide (Rybelsus): a comparative analysis of the medicine carbon footprint model and manufacturer life-cycle assessment in pharmaceutical production
BMJ open, 2026;16(9):e124968
Evoke (+) trials of semaglutide for early alzheimer’s disease: Innovations, lessons, and implications
The journal of prevention of Alzheimer's disease, 2026;13(10):100677
Predictors of Peak Body Weight Loss With Semaglutide in the SELECT Trial
Diabetes care, 2026
Incretin-Based Therapies: A Testable Hypothesis Linking Incretin Signaling, Mitochondrial Redox, and OXPHOS Efficiency
Obesity (Silver Spring, Md.), 2026
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Frontiers in endocrinology, 2026;17:1902185
SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis
Frontiers in pharmacology, 2026;17:1882227
Tirzepatide versus other anti-diabetic agents for the prevention of diabetic foot complications in patients with type 2 diabetes
Frontiers in pharmacology, 2026;17:1880132
GLP-1 receptor agonist use and postoperative complications after body contouring surgery following massive weight loss
Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2026;123:169-175
IcoSema in Weight Management and Glycaemic Control: A Systematic Review and Meta-Analysis
Cureus, 2026;18(9):e116875
Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease
Advances in therapy, 2026
GLP-1 receptor agonists and podocyte senescence in diabetic kidney disease: structural pharmacology, mechanistic evidence, and multi-receptor agonism
Biochemical pharmacology, 2026;:118495
[New Therapeutic Approaches for MASH: Mechanisms and Clinical Promise]
Zeitschrift fur Gastroenterologie, 2026;64(9):1250-1260
MASLD: Established Knowledge and Emerging Directions – Guideline Updates
Zeitschrift fur Gastroenterologie, 2026;64(9):1239-1249
Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial
European heart journal, 2026
Semaglutide mechanisms of action: the missing pieces
European heart journal, 2026
Delays in access to generic semaglutide point to key missing pieces in Canada’s drug approval system
Health policy (Amsterdam, Netherlands), 2026;174:105779
Semaglutide Reduces Odorant-Driven Chemotaxis and Reproductive Output in Caenorhabditis elegans
microPublication biology, 2026;2026
Tirzepatide for Weight Recurrence After Metabolic and Bariatric Surgery: A Critical Review of Direct and Indirect Evidence with Emphasis on Sleeve Gastrectomy, Nutritional Safety, and Clinical Implications
Nutrients, 2026;18(19)
Body Composition Changes With Standard Versus Low-Dose Tirzepatide Titration in Women With Lipedema: A Retrospective Observational Study
Cureus, 2026;18(9):e116779
Letter to the editor from Akinci and Oral: “Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy”
The Journal of clinical endocrinology and metabolism, 2026